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SUMMARY 
 
Title: Medulloblastoma: Diagnosis, Treatment and Prognosis 
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Author: Benjamin Aksungur 
 Medulloblastomas are embryonal tumors arising from the cerebellum and 
are the most common malignant brain tumors of childhood, with an incidence of 
10-25% of primary CNS neoplasms. Medulloblastomas in adults are less 
common but they do occur. Like many tumors the exact cause is unknown but 
changes have been identified in genes and chromosomes that may play a role 
in the development of these tumors. Although the cause is unknown there are 
several studies that have ruled out many environmental factors. 
Medulloblastomas are diagnosed by clinical presentation as well as diagnostic 
tools. Patients with medulloblastoma present with a history of headaches, 
emesis, and lethargy which are commonly subtle and intermittent. Symptoms 
are most often related to hydrocephalus secondary to obstruction of the fourth 
ventricle. Diagnostic tools such as the CT and MRI play a significant role in 
helping to initially diagnose medulloblastoma as well as the workup following the 
treatment and or resection. Histologically medulloblastomas can be classified 
into 7 different types, which is important for further treatment. The definitive 
diagnosis of medulloblastoma is made on microscopic pathologic examination. 
Current treatment of medulloblastoma consists of surgically removing as much 
of the tumor as possible, followed by craniospinal radiation and or 
chemotherapy. Treatment plans are based on factors that indicate the risk of 
recurrence. How well a patient responds to treatment is affected in general by 
their age at the time of diagnosis, the size and extent of the tumor, the amount 
of mass that can be removed safely and the level of metastatic disease. It is 
now becoming clear that patients with certain subgroups of medulloblastomas 
have better long-term outcome in comparison to the others.
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1. INTRODUCTION 
 
 While medulloblastoma is rare, it is the most common pediatric malignant 
brain tumor. It is a highly invasive neuroendothelial tumor that arises in the 
cerebellum located in the posterior fossa. This area is responsible for controlling 
balance posture and complex motor functions. Tumors located in this area of the 
brain are referred to as infratentorial tumors. This means that the tumor is 
located below the tentorium, which is a thick membrane that separates the 
larger cerebral hemisphere of the brain from the cerebellum. Medulloblastomas 
arise predominantly from the cerebellar vermis, which is a narrow worm like 
bridge that connects the cerebellum's two sides. Wheras in adults it mostly 
arises in the body of the cerebellum, especially towards the edges.1 
Medulloblastomas where previously classified as a PNETs however recent data 
has shown that these tumors are biologically distinct from other PNETs.2 It was 
introduced in 1925 by Bailey and Cushing and initially considered a subtype of 
gliomas and called spongioblastoma cerabelli and was later renamed to 
medulloblastoma.3 Over the years there has been significant debate about the 
most appropriate classification for small round cell tumors of the posterior fossa. 
It was found that histologically similar or identical tumors could be found in other 
areas of the brain, and collectively would be classfied as PNETs and subdivided 
on the basis of location, histologcal or clinical features.4 More recently studies 
have shown that tumors which arise in the posterior fossa are molecularly 
different than those arising in other regions of the brain. Medulloblastomas are 
now considered an entity that only arises in the posterior fossa. The WHO 
defines medulloblastoma as a malignant invasive embryonal tumor of the 
cerebellum with prefrential manifestion in children, predominantly neuronal 
differentiation and inherent tendancy to metastisaze via CSF with several 
subtypes.5 Due to the fact that they are classified into subgroups the treatment 
has moved away from a ”one therapy fits all” towards a more subgroup driven 
therapy. 
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2. AETIOLOGY  
 
 In general the aetiology of medulloblastoma remains unknown. These 
tumors form because of errors in the machinery in the cell that controls the 
growth and death. Changes have been identified in genes and chromosomes 
that may play a role in development, for example one half of all pediatric 
medulloblastomas contain alterations to portions of chromosome 17 while a 
much smaller proportion of tumors about 10% have a solitary deletion of 
chromosome 6.6 Inherited and familial medulloblastoma is extremely rare, 
nevertheless there are a few rare inherited health syndromes that are 
associated with increased risk for developing this tumor. Some examples of 
syndromes that contain specific genetic changes are Gorlins syndrome 
(PTCH1), Li Freumeni syndrome (p53), Turcots syndrome A (APC) and 
Rubenstein Taybi syndrome (CBP).7 While these syndromes are inherited the 
majority of medulloblastomas are not. However through the study of these 
syndromes genetic changes have been identified in medulloblastomas. With this 
advent of integrated genetics, studies have revealed that this tumor comprises 
at least four variants, which are transcriptionally, genetically, and clinically 
distinct. The four subgroups are termed, WNT, sonic hedgehog (SHH), group 3, 
group 4.2 The fact that the different molecular subgroups have been found to 
have a varied outcome is the most important recent discovery of 
medulloblastoma. These subgroups have significant prognostic values and 
predict survival independently of the presence of metastasis or unfavorable 
histology. Despite the fact that research has been conducted and the exact 
causes are unknown, several studies have ruled out environmental factors, 
including: aspartame, artificial sweeteners, smoking, alcohol or diet during 
pregnancy.6   
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 Medulloblastomas comprise approximately 25% of all pediatric brain 
tumors. No racial predispositions has been noted.8 Medulloblastoma can occur 
in all age groups with a peak age of incidence 3-5 years, most common in 
children younger than 9 years of age with a decreasing incidence after this age. 
Approximately 80% are diagnosed within the first 15 years of age. 
Medulloblastomas are not common in adults, but it does occur. One-fourth of 
diagnosed cases are found in adults between the ages of 20-44. The incidence 
in adults significantly declines after the age of 45. There exists a modest male 
preponderance in a ratio of 1.4:1, which is most noticeable in children younger 
than age 4.6 
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3. DIAGNOSIS 
  
3.1. Clinical Presentation  
 The clinical signs and symptoms initially seen with medulloblastoma are 
mostly asymptomatic or cause subtle clinical symptoms. Once symptoms do 
arise they are usually related to hydrocephalus secondary to obstruction of the 
fourth ventricle. Arising most commonly from the area of the cerebellar vermis, 
medulloblastomas cause neurologic symptoms by filling the fourth ventricle and 
blocking CSF egress or infiltrating cerebellar tissue.3 Most tumors are diagnosed 
when they are quite large and obstruct the flow of CSF. Symptoms are usually 
vague such as headaches, nausea or vomiting, problems with motor skills, 
tiredness, tilting of the head to one side, walking difficulty and balance problems. 
Almost all children with medulloblastoma present with symptoms of increased 
intracranial pressure specifically early morning vomiting and headache. The 
common sequence of events is early morning headache relieved by vomiting 
and resolution of symptoms. As the tumor progresses, the diurnal variation of 
the headache and vomiting tends to become less pronounced, and these 
symptoms are more constant.2 Other symptoms depend on the nerves and brain 
structures affected by the tumor. Since medulloblastomas appear in the 
cerebellum, the center of balance and movement, problems with dizziness and 
coordination are common. In addition to vomiting and headache truncal ataxia 
and diplopia secondary to sixth nerve palsy are also common presenting 
features. More lateral lesions may present with appendicular ataxia and 
occasionally focal weakness. Other neurologic symptoms localizing to the 
posterior fossa and brainstem can be present at diagnosis; nevertheless, they 
are much less common. Seizures rarely occur in children with medulloblastoma, 
and it is much more common for decerebrate posturing to be misinterpreted as 
tonic seizure. The time to diagnosis varies; nonetheless, children typically 
present acutely, and most often do not have a prediagnostic interval of longer 
than 2 months. Longer diagnostic times to not correlate to a poorer prognosis 
and consequences.  
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 The differential diagnosis for medulloblastoma at presentation includes 
ependymoma, pilocytic astrocytoma, atypical teratoid/rhabdoid tumor (AT/RT), 
and embryonal tumor with abundant neuropil and true rosettes (ETANTR).2 It 
can be difficult to differentiate these tumors based on clinical symptoms alone, 
even though children with pilocytic astrocytomas tend to have a longer duration 
of symptoms alone, and children with ependymomas have a history of neck pain 
or stiffness with associated torticollis due to caudal invasion of the tumor 
through the foramen magnum. 
 Infants and very young children present with a somewhat different clinical 
presentation. Due to their open sutures, infants present with macrocephaly and 
a head circumference that crosses percentiles. Infants with open sutures may 
present with irritability lethargy, bulging fontanels, downward gaze due to 
pressure on the pretectum, and developmental arrest or regression.1 Very young 
children also tend to present with more symptoms of hydrocephalus, such as 
apnea, bradycardia, and loss of consciousness, because of a more advanced 
stage of disease at diagnosis secondary to an increased tolerance of 
hydrocephalus. Adults commonly present with atypical symptoms and a longer 
prediagnostic interval because of a higher incidence of desmoplastic disease, 
which can arise in more lateral regions of the cerebellum. 
 Metastasis may present with symptoms of nerve root involvement or spinal 
cord symptoms, and is present in about 40% of patients at the time of diagnosis, 
most commonly being asymptomatic. Recurring disease is rarely diagnosed 
clinically; instead, it is diagnosed on routine serial neuroimaging, and the 
likelihood of recurrence decreases with time.9 
 
 The vast majority of medulloblastoma cases are sporadic (non-inherited). 
However, a small proportion of medulloblastoma cases occur in the context of 
hereditary syndromes which have an increased risk of cancer. Syndromes 
known to be associated with medulloblastoma include the following10: 
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Disease Gene(s)  Notes 
Basal Cell Nevus 
Syndrome  
PTCH1 
SMO SUFU 
PTCH2 
 
Basal Cell Nevus Syndrome (also known as Gorlin Syndrome) 
is an autosomal dominant condition characterised by the 
appearance of basal cell carcinomas, together with skeletal 
abnormalities, odontogenic keratocysts and increased risk of 
Medulloblastoma. Medulloblastoma develops in about 5 out of 
every 100 children with the syndrome. 
Fanconi Anaemia  BRCA2 
FANCD2 
PALB2 
FANCC 
FANCA 
 
Fanconi Anemia (FA) is a rare autosomal recessive genetic 
disorder characterised clinically by progressive bone marrow 
failure, skeletal deformities and a predisposition to leukaemia 
and a wide range of cancers. Affected children usually develop 
severe aplastic anemia by age 8 to 9 years. 
Li-Fraumeni 
syndrome 
TP53  
A rare inherited autosomal dominant disorder that greatly 
increases the risk of developing several types of cancer, 
particularly in children and young adults. The most frequent 
types of cancer associated with Li-Fraumeni syndrome are 
breast cancer, osteosarcoma, and soft tissue sarcomas. 
People affected also have increase risk of brain tumuors, 
leukaemias, adrenocortical carcinoma and other types of 
cancer.  
Rubinstein-Taybi 
Syndrome  
CREBBP 
EP300 
 
Rubinstein-Taybi Syndrome (RTS) ia an autosomal dominant 
chromosomal disorder characterized by broad thumbs, 
webbing of fingers and toes, mental retardation, beaked nose, 
short upper lip, pouting lower lip. Individuals with RTS have an 
increased risk of brain tumors and occasionally other tumours. 
Approximately 5 % of RTS patients develop a malignancy or a 
benign tumor. 
Turcot Syndrome MLH1 
PMS2 
APC 
MSH2 
MSH6 
 
Turcot Syndrome is characterised by malignant tumors of the 
central nervous system (mostly astrocytomas and 
medulloblastoma) associated with familial polyposis of the 
colon. There are different sub-types. 
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3.2. Imaging 
 Initially the diagnosis of medulloblastoma is usually made with non-contrast 
CT followed by MRI. On a noncontrast CT scan, a medulloblastoma is typically a 
hyperattenuating midline mass surrounded by vasogenic edema; it enhances 
homogeneously following the administration of contrast. Lateral cerebellar 
medulloblastomas are usually of desmoplastic histology. In at least 95% of 
patients hydrocephalus is present on the initial CT scan. CT findings for 
medulloblastoma are not specific and are difficult to distinguish from 
ependymoma or AT/RT.11 
 For posterior fossa tumors the preferred method of initial evaluation is an 
MRI with gadolinium enhancement (Fig.1,2,3). On T1-weighted MR imaging, 
medulloblastomas are hypointense or isointense relative to gray matter and 
become hyperintense with the administration of gadolinium. On T2-weighted 
imaging, the signal is variable and can be hyperintense to hypointense relative 
to gray matter.2 
 
Fig.1 – Axial MRI with gadolinium in patient with medulloblastoma 
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Fig. 2 –Sagittal MRI with gadolinium in patient with medulloblastoma 
 
Fig. 3 – Coronal MRI with gadolinium in patient with medulloblastoma 
 
 In differentiating medullolastoma from ependymoma or astrocytoma, 
diffusion weighted imaging can be very useful. Because medulloblastomas 
consist of dense small round cells with minimal cytoplasm and reduced free 
water, they exhibit diffusion restriction with a reduced apparent diffusion 
coefficient. Whereas ependymomas and pilocytic astrocytomas characteristically 
do not have restricted diffusion.2 AT/RTs also display restricted diffusion; 
conversely, young age of the patient, cerebellopontine angle involvement, and 
intratumoral hemorrhage can help distinguish AT/RTs from medulloblastomas 
radiologically.11 Due to the fact that 40% of meduloblastomas are metastatic at 
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the time of diagnosis, perioperative imagining of the entire craniospinal axis is 
desirable so that adequate staging can be established, when feasible. To avoid 
the possibility of false-positives due to debris and blood products, the imaging of 
the entire craniospinal axis should be performed 2 weeks or later 
postoperatively for full staging.12 Cranial MR imaging should also be repeated 
within 72 hours postoperatively or after 2 weeks postoperatively because a 
residual tumor of more than 1.5 cm2 may be correlated with a higher risk for 
disease, if performed between 3-14 days there is a risk of false positive.12 For a 
conclusive diagnosis, pathologic diagnosis is required.  
 Lumbar CSF is also acceptable in every patient diagnosed with 
medulloblastoma. Lumbar sampling is preferred over ventricular sampling at 
surgery or through a shunt because lumbar CSF sampling is more sensitive 
than ventricular sampling.13 Preferably, both ventricular CSF sampling at 
surgery and lumbar CSF sampling 2 weeks postoperatively should be obtained 
because the two sites can contraindicate each other, and a positive ventricular 
CSF cytology intraoperatively has been associated with a poorer outcome.13  
 If extraneural disease is suspected, FDG-PET (fluorodeoxyglucose F 18 
positron emission tomography) and bone marrow biopsy are the preferred 
modalities. Extraneural disease is present more commonly at recurrence, 
predominantly very late recurrences, and can be present in the absence of 
intracranial disease.14 Due to ototoxic and nephrotoxic effects of both platinum-
based chemotherapy and radiotherapy, hearing and creatinine clearance should 
be evaluated postoperatively in all patients before the initiation of either 
chemotherapy or radiotherapy.  
 
3.3.Hydrochepalus  
 Patients with medulloblastoma most commonly have symptoms related to 
increased intracranial pressure (as a consequence of hydrocephalus) (Fig.4). 
Symptoms usually precede presentation by no more than 2 months. As such, 
the management of hydrocephalus is usually the first step. Symptoms that 
present in relation to hydrocephalus, are related to the age of the patient. 
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Younger non-verbal patients present with behavioral changes. Symptoms in 
younger children include lethargy, irritability, vomiting, and decreased social 
interactions. Older children and adults complain of headache, especially upon 
awakening in the morning. Vomiting without nausea is more common in the 
morning, since being recumbent increases intracranial pressure. Patients may 
develop double vision as the sixth cranial nerve becomes stretched from the 
hydrocephalus. Visual disturbances more commonly are a result of papilledema. 
 
Fig.4 - Periventricular hypointensity suggesting hydrocephalus 
  Most patients can be managed with preoperative dexamethasone (0.45 
mg/kg per day divided into three doses, with an initial dose of 0.45 mg/kg), 
which results in significant alleviation of the symptoms and a reduction in 
vomiting. Placing an EVD preoperatively is occasionally necessary. When an 
EVD is placed, consideration must be given to the possibility of upward 
herniation, and the rate and quantity of CSF drainage must be carefully 
monitored. During the postoperative period the height of an EVD can be 
gradually increased, and in most cases the EVD can be successfully removed 
within a week to 10 days postoperatively.15 Routine ventriculoperitoneal 
shunting is not indicated perioperatively, as 10 to 40% of children require 
permanent CSF diversion postoperatively. Among the indications for shunting 
are, young children and in those with very large ventricles at diagnosis, more 
extensive tumors, and metastatic disease15. When persistent hydrocephalus is 
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present, either ventriculoperitoneal shunting or endoscopic third ventriculostomy 
can be considered.16 Several series have reported high success rates with 
endoscopic third ventriculostomy for persistent hydrocephalus, and it should be 
considered in patients requiring postoperative shunting who are suitable 
candidates for this procedure. 
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4. CLASSIFICATION, STAGING AND PATHOLOGY 
Pathology 
 Microscopic pathologic examination remains the primary way of making a 
definitive medulloblastoma diagnosis. The characteristic microscopic appearance 
is that of a “small round blue cell tumor” which is morphologically 
indistinguishable from supratentorial PNETs or pineoblastomas. Histologically, 
there are three main types of medulloblastoma: (1) classic (Fig.5), (2) 
desmoplastic (Fig.6), and (3) large cell/anaplastic (Fig.7). The classic variant is 
by far the most common histology (>70%), while desmoplastic histology is more 
common in infants and adults and is most commonly associated with the SHH 
pathway activation. Large cell/anaplastic medulloblastoma is aggressive and 
more common in the group 3 molecular subgroup with a poor prognosis.  
 
 
Fig. 5 - Medulloblastoma (WHO grade IV)  classic variant , histology composed of densely 
packed cells with round to oval hyperchromatic nuclei surrounded by scanty cytoplasm. Area with 
Homer Wright rosettes  (H & E  stain x 20). 
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Fig. 6 - Medulloblastoma (WHO grade IV), desmoplastic/nodular variant (HE x 10). 
 
 
Fig. 7 - Medulloblastoma (WHO grade IV) anaplastic/ large cells variant (HE x 20). 
 
 Through the use of integrated genomics, at least four molecular variants of 
medulloblastoma have been described and identified. The importance of this 
classification is that each group has a unique transcriptional and genetic profile 
which creates clinically distinct presentations.2 
 The four molecular subgroups are termed WNT, sonic hedgehog (SHH 
group), group 3, and group 4.17-19 These subgroups have significant prognostic 
value that is independent of the presence of metastases or unfavourable 
histology. The WNT subgroup is characterised by activation of the WNT pathway, 
and tumors commonly harbor mutations in the beta-catenin gene (CTNNB1). 
 14 
 
These tumors primarily occur outside the infant age group and tend to carry a 
favourable prognosis with rare occurrence of metastases. The SHH sub group is 
characterized by activation of the SHH pathway and is more common in infants 
with desmoplastic tumors and in adults; however, it can occur in all age groups 
and is associated with all histological variants. Prognosis tends to be good for 
infants and intermediate for others. Group 3 medulloblastomas have a poor 
prognosis and are commonly associated with metastatic disease. Infants and 
children are the primarily affected populations. MYC amplification is common in 
group 3 medulloblastomas, and the survival rate in these patients is dismal.  
Group 4 tumors have an intermediate prognosis and are associated with 
isochromosome 17q and MYCN amplification. All age groups are affected and 
metastases frequently occur. (Fig.8) 
 
 
Fig. 8 
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Staging 
 The staging of medulloblastoma is based on the modified Chang’s staging 
system. Patients are risk stratified into either an average risk group or high risk 
group based on the tumor stage, patient’s age, and the extent of any previous 
surgical resection.20 
 
T1 Tumor <3 cm in diameter 
T2 Tumor >3 cm in diameter 
T3a Tumor >3 cm in diameter with extension 
T3b Tumor >3 cm in diameter with unequivocal extension into the brainstem 
T4 Tumor >3 cm in diameter with extension up past the aqueduct of Sylvius 
and/or down past the foramen magnum (ie. Beyond the posterior fossa) 
M0 No evidence of subarachnoid or hematogenous metastasis 
M1 Tumor cells found in cerebrospinal fluid 
M2 Intracranial tumor beyond primary site 
M3 Gross nodular seeding in spinal subarachnoid space 
M4 Metastasis outside the cerebrospinal axis (especially to bone marrow, 
bone) 
 
Children older than age 3 are categorised as having average-risk or high-
risk diseases based on the Chang staging system. The prognosis of patients with 
metastases does not differ for M1, M2, and M3. All patients older than the age of 
3 years with no evidence of disseminated diseases and residual tumor at the 
primary site of less than 1.5 cm2 are classified as having average-risk 
medulloblastoma. All patients younger than age 3 are designated as high-risk. 
Patients older than age 3 with average risk diseases have a 5-year survival rate 
of 85% with combined chemotherapy and reduced-dose radiotherapy, and 
patients older than age 3 with high-risk disease have a 5 year survival rate of 
70% with combined chemotherapy and high-dose radiation therapy. In children 
younger than 3, histology is predictive of outcome. 
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5. TREATMENT 
5.1. Surgical 
 
 The most common initial treatment for medulloblastoma is gross total 
resection of the primary posterior fossa mass through a suboccipital craniotomy. 
The aim of surgical resection is to completely remove the entire tumor or, if this 
is not possible, to resect as much of the tumor as is safely possible. 
The craniotomy is preformed with the patient in the prone position and the neck 
flexed. Initially superficial tissues and muscles are dissected, and a portion of 
the occipital bone and the laminae of C1 are removed. The dura covering the 
cerebellum is then opened, and the two hemispheres are retracted through 
either the split vermis or a telovelar approach. At the beginning of surgery it is 
important to visualize the floor of the 4th ventricle to confirm that the resection is 
not carried into the brainstem, even though this tumor rarely invades the floor. If 
the surgeon resects a tumor that invades the brainstem, severe cranial nerve 
palsies can result, and this is never indicated because the tumor is sensitive to 
both chemotherapy and radiation, and residual brainstem disease likely does 
not significantly alter the outcome.21 The use of intraoperative brainstem 
auditory evoked potentials can be considered if the tumor invades the 
cerebellopontine angle. Particularly in young children, care should be taken to 
prevent blood loss, as medulloblastomas can be fairly vascular, leading to 
considerable hemorrhage intraoperatively. Closing of the dura should be 
achieved in a watertight manner and the bone replaced after the procedure has 
been preformed. Within 72 hours of surgery a post operative MRI should be 
preformed to determine the extent of the resection as well to avoid obscuration 
by blood products and gliosis. A poorer outcome is possibly associated with 
residual disease over 1.5 cm2, and repeated resection for a large residual tumor 
should be considered unless the surgeon stopped the initial resection because 
of excessive vascularity or invasion of critical structures. 
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5.2. Complications 
 
 The most common postoperative complication is the posterior fossa 
syndrome, also referred to as cerebellar mutism or cerebellar affective 
syndrome. A study showed that approximately 22% of patient developed 
posterior fossa syndrome postoperatively, however these cases were rated as 
moderate to severe, suggesting that the incidence of milder cases maybe much 
higher.22 The symptoms typically manifest 24-48 hours postoperatively.23 This 
syndrome is characterized by a triad of (1) decreased production of speech or 
mutism, (2) to cerebellar dysfunction including ataxia and axial hypotonia, and 
(3) neurobehavioural affective symptoms such as emotional liability, irritability, 
and apathy.24,25 Nonverbal children are typically inconsolable with sharp, high 
pitched wining and display marked apathy with a lack of initiation and 
hypokinesis. In up to 60% of patients fecal and urinary incontinence have been 
observed. The pathophysiology is not completely known and is beyond the 
scope of this paper. There is recent evidence of presurgical language 
impairment as the primary risk factor for the development of the posterior fossa 
syndrome; children without a presurgical language deficit did not develop 
mutism, suggesting that the technical aspects of surgery are unlikely to be 
causative.26 Conclusive of this information is that surgical approaches that avoid 
splitting the cerebellar vermis do not seem to prevent the development of this 
syndrome. The outcome of posterior fossa syndrome is variable. Classically 
children recover from mutism within 8 weeks, although residual ataxic dysarthria 
is common. 95% of patients with moderate or severe mutism one year 
postoperatively had speech impairments.22 Other known neuropsychiatric 
deficits noted in patients with this syndrome, are deficits in receptive language, 
memory impairment, cognitive function, and executive function, indicating that 
multidisciplinary rehabilitation is required in these patients.22,25 There are no 
available methods for either the prevention or treatment of posterior fossa 
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syndrome that have been shown to be effective beyond the level of anecdotal 
reports. 
5.3. Non-Surgical Treatment  
  
RADIATION THERAPY 
 
 Patients older than three years of age with an average risk disease are 
treated with a reduced dose (2,340 cGy) craniospinal irradiation, with a boost to 
the tumor bed or posterior fossa of 5,400 to 5,580 Gy after surgical resection of 
the primary tumor.17,18 Following radiation therapy and adjuvant cisplatin based 
chemotherapy in patients with average risk disease results in survivals rates of 
approximately 85%. Patients who have high risk disease are treated with 3,600 
cGy of craniospinal irradiation, with a boost to the tumor bed and to focal 
metastases followed by adjuvant chemotherapy, leading to a survival rate of 
approximately 70%. Delaying radiotherapy for more then 28 days 
postoperatively has negative prognostic impact.27 Several adverse effects are 
associated with radiation therapy, predominantly cognitive impairment in 
younger children. Frequently observed side effects of radiation therapy are 
autotoxicity, thyroid dysfunction, growth failure, and radiation necrosis, which 
are inversely correlated with age. Children younger than age 3 have devastating 
cognitive outcomes when receiving irradiation and due to this protocols using 
chemotherapy alone are preferred despite inferior outcomes.28 
 
CHEMOTHERAPY 
 
 Chemotherapy is included in current therapy for all patients with 
medulloblastoma. Children under the age of 3 even in disseminated cases are 
treated with chemotherapy only approaches. Three approaches have been 
studied for infant medulloblastoma, including systemic induction chemotherapy, 
followed by myeloablative chemotherapy with autologous stem cell support, 
followed by a radiotherapy for local relapse, combined systemic and 
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intraventricular chemotherapy, and systemic therapy with conformal local 
radiotherapy.29 Five year survival rates of approximately 50-70% are accepted in 
all three of these approaches, with the desmoplastic variant having survivals 
close to 90%.29 The intraventricular methotrexate approach requires the 
placement of a catheter or a shunt and adequate CSF flow. Methotrexate should 
not be given through a ventriculoperitoneal shunt without a device for transient 
occlusion to prevent drug induced peritonitis. Also, intraventricular methotrexate 
is associated with a dose dependent leukoencephalopathy of varying severity, 
and patients are at risk for radiation necrosis if they are also undergoing 
radiation therapy. A high risk for developing significant cognitive deficits 
(measures of intelligence and memory), is seen in young children treated with 
intrathecal methotrexate. Patients older than age 3 with average risk disease 
are treated with 4-9 cycles of combination post irradiation adjuvant 
chemotherapy which is usually cisplatin based. In patient with high risk disease 
a variety of approaches have been used to treat medulloblastoma, ultimately all 
of these approaches administer adjuvant chemotherapy following high dose 
craniospinal irradiation, leading to 5 year survival rates of approximately 70%.30 
Chemotherapeutic options are limited for recurrent disease, particularly in 
children with prior irradiation. A possibility is the use of high dose chemotherapy 
with autologous stem cell support with or without repeated irradiation, which can 
result in long term survival in 10-25 % of patients.31 Although studies suggest 
that the outcome is favorable only in those patients with no evidence of disease 
or minimal residual disease at the time of high dose chemotherapy. 
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6. PROGNOSIS 
 
Although the clinical criteria used to assign prognostic outcomes to the 
different risk groups continue to evolve, three features are currently used: 
metastases at presentation, the extent of postoperative residual disease and 
age. Risk groups are defined as follows: 
 Average risk disease-Patients older than 3 years, stage M0 and with less 
than 1.5cm2 of residual tumor post operatively. The 5- year survival rate is 
currently 78%. 
 Poor risk disease-Patients older than 3 years, stage M1-M4 and/or with 
more than 1.5cm2 of residual tumor postoperatively. The 5-year survival 
rate is currently 30-55%. Patients with anaplastic tumors are also 
considered in this risk group.  
 Patients with non-posterior fossa tumors that are morphologically similar 
to medulloblastoma (primitive neural ectodermal tumors) have a poor 
prognosis similar to that of patients with poor-risk medulloblastoma, 
regardless of dissemination.  
 Patients under the age of 3 years are defined as infants. Unfortunately, 
the worst prognosis occurs with this group, regardless of M stage and 
extent of postoperative residual disease. The 5-year survival rate is 
approximately 30%. Metastatic disease further worsens the prognostic 
outlook.  
Even with a good response to surgery and radiation, recurrence in adults is 
common and these often occur within 2 years after treatment.32 Recurrences 
tend to occur at the primary site in the posterior fossa. The incidence of 
recurrence in the spinal canal and the supratentorial region seems to decrease 
with the use of adjuvant chemotherapy.  
 
Collin’s law, known as period of risk for recurrence (PRR), has been 
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discussed as a reliable outline for the prediction of recurrence or cure of 
embryonal tumors including medulloblastoma. The PRR is defined as the age at 
diagnosis plus 9 months of gestation (reference pubmed). According to Collin’s 
law, a patient who has no clinical evidence of recurrence within this time period is 
considered cured.33 
 
More recently, histopathology and molecular subtyping studies have 
identified more specific groups for which survival ranges from excellent to very 
poor (1-4). How the histopathology and molecular grouping affects the use of 
radiation therapy remains to be determined.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
 
 
7. CONCLUSION 
 
 Medulloblastoma is the most common malignant brain tumor in childhood, 
with proper diagnosis and treatment prognosis can be very favorable. The vast 
majority of medulloblastomas occur before the age of 16, and there is a bimodal 
peak of incidence between ages 3-4 years and 8-9 years, males are affected 
more frequently than females with a ratio of 1.4:1. Adult cases are unusual, 
accounting for less than 1% of braintumors. The tumor is rare beyond the fifth 
decade. Due to the location of medulloblastomas clinical signs and symptoms 
are usually related to hydrocephalus secondary to the obstruction of the fourth 
ventricle. The Initial diagnosis of medulloblastoma is usually made with 
noncontrast CT followed by MRI. The definitive diagnosis of medulloblastoma is 
made on microscopic pathologic examination, which also influences the 
treatment and prognosis of these patients. The most commonly used system of 
staging for medulloblastoma is the chang system which accounts for the size 
and the invasiveness of the tumor. the WHO classification system for 
medulloblastomas uses histology to classify medulloblastomas in to 3 major 
groups. Current treatment strategies for medulloblastoma are developed based 
on the risk stratification and the age of the patient. In all subgropus of patients, 
surgery is the first line treatment, which aims for maximal tumor resection. 
Postsurgical treatment further varies between higher risk groups and low risk 
groups receiving different combinations of chemotherapy and radiotherapy. 
Prognosis is greatly influenced by a combination of factors with an overall 5 
years survival rate currently around 60%. 
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